ANVS
Annovis Bio Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
annovis bio, inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. its lead compound is anvs401, which is in phase 2a clinical trials for the treatment of alzheimer's disease (ad), parkinson's disease, alzheimer's disease in down syndrome, and other chronic neurodegenerative disorders. the company is also developing anvs405 for protecting the brain after traumatic brain injury and/or stroke; and anvs301, which is in phase i clinical trials to increase cognitive capability in later stages of ad and dementia. annovis bio, inc. was founded in 2008 and is based in berwyn, pennsylvania.
Market Cap: 98.9 Million
Primary Exchange: NEW YORK STOCK EXCHANGE INC.
Website: https://www.annovisbio.com/
Shares Outstanding: 10.6 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.8154470361506969
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 868 trading days
From: 2021-07-13 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|